Clinical trials: Blood Platelet Disease
Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions
Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction
The research is planned as a prospective nested case-control study. The plan is to recruit about 1,200 consecutive subjects whose pharmacotherapy involves the drug(s) of interest within 4.5 years.
- Conditions
- Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Drugs
- Trial name
- NCT05307718
- Testing
- Oral Anticoagulant, Direct-Acting
- Where
- Croatia
- Volunteers
- 1,200 people
- Sponsor
- Clinical Hospital Centre Zagreb
Von Willebrand Diseases
REAL-LIFE DATA OF CONSTITUTIONAL VON WILLEBRAND DISEASE IN WESTERN FRANCE (HOPSCOTcH-WILL)
Von Willebrand disease (VWD) is the most common constitutional bleeding disorder in the world, caused by missing or defective von Willebrand factor (VWF). In France, VWD affects approximatively 7,000 patients.
- Trial name
- NCT03875924
- Testing
- VWD treatments
- Where
- 5 sites in France
- Volunteers
- 926 people
- Sponsor
- Nantes University Hospital
Thrombocytopenia
Retrospective Study of Romiplostim for Platelet Engraftment After Allo-HSCT
This is a retrospective observational study evaluating the efficacy and safety of romiplostim for promoting platelet engraftment in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Tongji…
- Trial name
- NCT07747246
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Tongji Hospital
TMJ Disc Disorder
Treatment of Tempromandibular Joint Anterior Disc Displacement With Different Materials
comparing the clinical efficacy of intra-articular injection of platelet lysate (PL), versus Hyaluronic Acid after arthrocentesis in the management of patients with anterior disc displacement with reduction.
- Trial name
- NCT06441279
- Testing
- intra-articular injection with Platelet lysate (PL)., intra-articular injection with Hyaluronic Acid.
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Von Willebrand Disease
Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
The primary objective of this study is to describe characteristics and trends for thrombin generation (TG) and thromboelastography (TEG) at 4 time points during the menstrual cycle.
- Trial name
- NCT00178542
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center, Houston
Gingival Recession
Platelet-Rich Fibrin Dressing in the Management of Free Gingival Graft
Evaluation of two dressing materials; a Platelet-Rich Fibrin (PRF) dressing and a non-eugenol-based (Coe-Pak™) dressing in the management of free gingival graft and donor site palatal wound.
- Trial name
- NCT03589235
- Testing
- A free gingival graft, A Platelet-Rich Fibrin dressing, A non-eugenol-based dressing
- Where
- Syria
- Volunteers
- 20 people
- Sponsor
- Damascus University
Chronic Myeloproliferative Neoplasms
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
This is a multicenter, open label, long-term study testing the long-term safety, tolerability and efficacy of givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera…
- Trial name
- NCT01761968
- Testing
- givinostat
- Where
- 15 sites in Germany, Italy and 1 more
- Volunteers
- 90 people
- Sponsor
- Italfarmaco
Olfactory Dysfunction, Anosmia
Topical Versus Injection PRP for Olfactory Dysfunction
The goal of this clinical trial is to determine whether two different delivery methods of autologous platelet-rich plasma (PRP) can improve olfactory function in adults with persistent olfactory dysfunction lasting more than…
- Conditions
- Olfactory Dysfunction, Anosmia, Hyposmia
- Trial name
- TOP-IN (NCT07151703)
- Testing
- Intranasal Injection of Autologous PRP, Carrier-Assisted Topical Application of Autologous PRP, platelet-rich plasma
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Primary Immune Thrombocytopenia (ITP)
Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP
To address the clinical need for improving early response rates, maintaining sustained responses, reducing relapse rates, and minimizing adverse events in the treatment of immune thrombocytopenia (ITP), the investigators…
- Trial name
- NCT07189910
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Acute Myeloid Leukemia
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
This was an open-label pilot study that evaluated the safety and preliminary evidence of a therapeutic effect of dociparstat in conjunction with standard induction and consolidation therapy for acute myeloid leukemia (AML).
- Trial name
- PGX-AML (NCT02056782)
- Testing
- Dociparstat sodium
- Volunteers
- 12 people
- Sponsor
- Jazz Pharmaceuticals
Stress Urinary Incontinence
Peri-Urethral Platelet-Rich Plasma Injections for Postmenopausal Female Stress Urinary Incontinence
his prospective interventional study will evaluate the effectiveness and safety of peri-urethral injections of platelet-rich plasma for treating stress urinary incontinence in postmenopausal women.
- Trial name
- NCT07807982
- Testing
- Autologous Platelet-Rich Plasma
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Benha University
Sickle Cell Disease, Venous Thromboembolism
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation.
- Trial name
- DrepAgreg (NCT07852442)
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Myelofibrosis, Thrombocytopenia
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Fostamatinib may improve thrombocytopenia in myelofibrosis patients with severe thrombocytopenia (platelet <50,000/microL) and allow them to initiate treatment with a JAK2 inhibitor, ruxolitinib.
- Trial name
- NCT04543279
- Testing
- Fostamatinib, Ruxolitinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Washington University School of Medicine
Gingival Recession
Evaluating Coronally Advanced Flap With Platelet-rich Fibrin Membrane and Chorion Membrane for Gingival Recession
The present study was a double-blind, randomised, controlled clinical trial with a parallel design, comparing the coronally advanced flap (CAF) with platelet-rich fibrin (PRF) and chorion membrane (CM) for the treatment of…
- Trial name
- NCT07308405
- Testing
- Coronally advanced flap (CAF) with platelet-rich fibrin (PRF), A similar surgical procedure was followed for the recipient bed preparation similar to that for the PRF membrane. A chorion membrane (Tissue bank, Tata Memorial Hospital, Mumbai, Maharashtra, India) o
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institute of Dental Sciences, Bareilly, Uttar Pradesh, India
Thrombocythemia, Essential, Primary Myelofibrosis
An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior…
- Trial name
- NCT05223920
- Testing
- Bomedemstat
- Where
- 19 sites in United States, Australia and 5 more
- Volunteers
- 81 people
- Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Primary Immune Thrombocytopenia
Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP
The goal of this clinical trial is to learn if romiplostim N01 works to treat severe primary immune thrombocytopenia in adults. It will also learn about the safety of romiplostim N01.
- Trial name
- NCT06686927
- Testing
- corticosteroids combined with immunoglobulin and romiplostim
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Androgenetic Alopecia
Efficacy of Platelet-Rich Plasma Therapy for Androgenetic Alopecia: A Systematic Review and Meta-analysis
assess the literature on PRP outcomes for AGA, with a focus on specific clinical outcomes in a comparative view, in accordance with PRISMA statement for reporting this meta-analysis
- Trial name
- PRP IN AGA (NCT04191005)
- Where
- Egypt
- Volunteers
- 15 people
- Sponsor
- Jasim Mohammed Alshammari
Immune Thrombocytopenic Purpura (ITP)
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06722235
- Testing
- Mezagitamab
- Where
- 124 sites in United States, Australia and 16 more
- Volunteers
- 171 people
- Sponsor
- Takeda
Osteoarthritis, Knee
PRP-HA Versus HA in Knee Osteoarthritis
Osteoarthritis (OA) is a prevalent chronic condition which most commonly affects the knee. The pathogenesis of OA involves initial mechanical stress resulting in cartilage lesions, leading to inflammatory processes causing joint…
- Trial name
- NCT05076526
- Testing
- Hyaluronic acid (Synolis VA), Cellular Matrix platelet-rich-plasma with hyaluronic acid (CM PRP-HA)
- Volunteers
- 132 people
- Sponsor
- Singapore General Hospital
Myelofibrosis, Myelodysplastic Syndrome
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
- Conditions
- Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
- Trial name
- LIMBER (NCT04279847)
- Testing
- INCB057643, Ruxolitinib
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 140 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.